EASL 2014 Edward Gane of Auckland Clinical Studies, New Zealand, presenting at EASL 2014; photo by Liz Highleyman, hivandhepatitis.com Sofosbuvir/ledipasvirCo-formulation is safe and effective for relapsers and hard-to-treat patients Guidelines panel at the International Liver Congress 2014. Photo by Liz Highleyman, hivandhepatitis.com.New EASL guidelinesEuropean liver specialists recommend use of newest hepatitis C drugs Professor Stefan Zeuzem speaking at the International Liver Congress 2014. Photo by Liz Highleyman, hivandhepatitis.com.Interferon-free regimenAbbVie regimen cures 96% of treatment-experienced people with HCV genotype 1 infohep news Fatigue Sustained response to treatment reduces fatigue in people with hepatitis C Keith Alcorn / 30 May 2014 Curative treatment that eliminates hepatitis C virus (HCV) from the body can reduce central fatigue, one of the most concerning symptoms associated with chronic hepatitis C, according to research presented at the ... Treatment in liver transplanted Sofosbuvir + ribavirin is safe and effective for HCV recurrence after liver transplantation Liz Highleyman / 29 May 2014 An interferon-free combination of sofosbuvir (Sovaldi) plus ribavirin taken for up to 24 weeks led to sustained virological response in 70% of liver transplant recipients with hepatitis C virus (HCV) recurrence, according to ... Interferon-free regimens Sofosbuvir + ribavirin for 24 weeks is highly effective against HCV genotype 4 Liz Highleyman / 28 May 2014 A 24-week regimen of sofosbuvir (Sovaldi) plus ribavirin cured 93% of people with hard-to-treat hepatitis C virus genotype 4, though treatment for only 12 weeks was not as effective, according to a ... Interferon treatment for HBV Adding interferon to nucleoside antivirals may improve response for people with chronic hepatitis B Liz Highleyman / 24 April 2014 Adding pegylated interferon to entecavir (Baraclude) led to greater hepatitis B virus (HBV) viral load decline and higher likelihood of serological response in people with HBeAg-positive chronic hepatitis B, as did added interferon after ... Interferon-free regimens MK-5172 + MK-8742 demonstrate good early post-treatment response rates Liz Highleyman / 24 April 2014 A combination of two direct-acting antivirals, MK-5172 and MK-8742, with or without ribavirin, led to early post-treatment sustained response rates above 90% for people with genotype 1 hepatitis C virus (HCV), including ... Treatment for previous non-responders & relapsers Sofosbuvir for hepatitis C works well despite multiple negative predictive factors Liz Highleyman / 24 April 2014 Hepatitis C treatment using sofosbuvir (Sovaldi) is highly effective even for people with multiple factors traditionally associated with poor response. Having four or more negative predictive factors, however, raises the risk of post-treatment relapse, ... Hepatitis delta Prolonged pegylated interferon plus tenofovir does not prevent hepatitis delta relapse Liz Highleyman / 23 April 2014 Treating hepatitis B patients with hepatitis delta virus (HDV) co-infection using pegylated interferon plus tenofovir (Viread) for 96 weeks may reduce HDV viral load, but side-effects are frequent and it did not significantly improve ... Treatment in liver transplanted Three-drug AbbVie combination safe and highly effective in treatment of post-transplant hepatitis C recurrence Keith Alcorn / 23 April 2014 A three-drug combination of direct-acting antivirals developed by AbbVie cured hepatitis C genotype 1 infection in 96% of transplant recipients with recurrent hepatitis C in a small phase II study reported at ... Genotype 4 AbbVie 2-drug combination + ribavirin achieves 100% cure in previously untreated genotype 4 hepatitis C Keith Alcorn / 22 April 2014 A combination of two direct-acting antivirals developed by AbbVie cured 100% of previously untreated patients with hepatitis C genotype 4 infection when used with ribavirin, Christophe Hézode reported on Friday at the ... Cirrhosis AbbVie 3-drug combination cures 92 to 96% of hepatitis C patients with cirrhosis Keith Alcorn / 22 April 2014 The largest study of new direct-acting antivirals yet conducted in people with hepatitis C genotype 1 who have compensated cirrhosis has shown that it is possible to cure between 92 and 96% ... View more > Editors' picks from other sources Activism and civil society Activists protest the price of sofosbuvir: “So-Valdi, So-Expensive” – UK access already rationed i-Base / 28 May 2014 Health services, policy and advocacy Eliminating Hepatitis C Within a Generation. What are you going to do about it? You Tube / Jon Derricott / 30 April 2014 Epidemiology Viral hepatitis more deadly than HIV in Europe Science Daily / 14 April 2014 Epidemiology Viral Hepatitis More Deadly Than HIV In Europe EASL / 11 April 2014 Interferon-free regimens Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Naïve Patients with Genotype 1 Infection Merck press release / 11 April 2014 Finance, funding & health economics U.S. drug industry group defends price of Gilead hepatitis drug Reuters / 11 April 2014 Access to medicines & diagnostics Sofosbuvir: Gilead must commit to compassionate use & expanded access EATG / 10 April 2014 Treatment guidelines WHO issues its first hepatitis C treatment guidelines World Health Organization / 09 April 2014 Access to medicines & diagnostics WHO joins clamour to make new hepatitis C pills affordable Reuters / 09 April 2014 View more > Other pages in this section Latest news All the news Conference news Email bulletin archive